Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
Multiple Sclerosis International
Volume 2012, Article ID 452541, 7 pages
http://dx.doi.org/10.1155/2012/452541
Clinical Study

Effects of Adjunct Low-Dose Vitamin D on Relapsing-Remitting Multiple Sclerosis Progression: Preliminary Findings of a Randomized Placebo-Controlled Trial

1Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 8144503500, Iran
2Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan 8144503500, Iran

Received 16 November 2011; Accepted 13 February 2012

Academic Editor: Francesco Patti

Copyright © 2012 Vahid Shaygannejad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. G. Clanet and D. Brassat, “The management of multiple sclerosis patients,” Current Opinion in Neurology, vol. 13, no. 3, pp. 263–270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. R. G. Richards, F. C. Sampson, S. M. Beard, and P. Tappenden, “A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models,” Health Technology Assessment, vol. 6, no. 10, pp. 1–73, 2002. View at Google Scholar · View at Scopus
  3. W. M. Davis, “Multiple sclerosis: continuing mysteries and current management,” Drug Topics, vol. 144, no. 12, pp. 93–102, 2000. View at Google Scholar · View at Scopus
  4. C. H. Polman and B. M. J. Uitdehaag, “Drug treatment of multiple sclerosis,” British Medical Journal, vol. 321, no. 7259, pp. 490–494, 2000. View at Google Scholar · View at Scopus
  5. A. Miller, “Current and investigational therapies used to alter the course of disease in multiple sclerosis,” Southern Medical Journal, vol. 90, no. 4, pp. 367–375, 1997. View at Google Scholar · View at Scopus
  6. D. A. Hafler, J. M. Slavik, D. E. Anderson, K. C. O'Connor, P. De Jager, and C. Baecher-Allan, “Multiple sclerosis,” Immunological Reviews, vol. 204, pp. 208–231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. L. Galetta and C. Markowitz, “US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles,” CNS Drugs, vol. 19, no. 3, pp. 239–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. D. M. Provvedini, C. D. Tsoukas, L. J. Deftos, and S. C. Manolagas, “1,25-Dihydroxyvitamin D3 receptors in human leukocytes,” Science, vol. 221, no. 4616, pp. 1181–1183, 1983. View at Google Scholar · View at Scopus
  9. A. K. Bhalla, E. P. Amento, and T. L. Clemens, “Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation,” Journal of Clinical Endocrinology and Metabolism, vol. 57, no. 6, pp. 1308–1310, 1983. View at Google Scholar
  10. H. F. Deluca and M. T. Cantorna, “Vitamin D: its role and uses in immunology,” The FASEB Journal, vol. 15, no. 14, pp. 2579–2585, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Niino, “Vitamin D and its immunoregulatory role in multiple sclerosis,” Drugs of Today, vol. 46, no. 4, pp. 279–290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. T. Cantorna, C. E. Hayes, and H. F. Deluca, “1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 15, pp. 7861–7864, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. K. L. Munger, S. M. Zhang, E. O'Reilly et al., “Vitamin D intake and incidence of multiple sclerosis,” Neurology, vol. 62, no. 1, pp. 60–65, 2004. View at Google Scholar · View at Scopus
  14. J. M. Burton, S. Kimball, R. Vieth et al., “A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis,” Neurology, vol. 74, no. 23, pp. 1852–1859, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Goldberg, M. C. Fleming, and E. H. Picard, “Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D,” Medical Hypotheses, vol. 21, no. 2, pp. 193–200, 1986. View at Google Scholar · View at Scopus
  16. D. M. Wingerchuk, J. Lesaux, G. P. A. Rice, M. Kremenchutzky, and G. C. Ebers, “A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 9, pp. 1294–1296, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Achiron, Y. Barak, S. Miron, Y. Izhak, M. Faibel, and S. Edelstein, “Alfacalcidol treatment in multiple sclerosis,” Clinical Neuropharmacology, vol. 26, no. 2, p. 53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J. O. Fleming, A. L. Hummel, B. R. Beinlich et al., “Vitamin D treatment of relapsing—remitting multiple sclerosis (RRMS): a MRI-based pilot study,” Neurology, vol. 54, supplement 3, p. A338, 2000. View at Google Scholar
  19. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. W. B. Grant and M. F. Holick, “Benefits and requirements of vitamin D for optimal health: a review,” Alternative Medicine Review, vol. 10, no. 2, pp. 94–111, 2005. View at Google Scholar · View at Scopus
  21. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Google Scholar · View at Scopus
  22. M. S. Stein, Y. Liu, O. M. Gray et al., “A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis,” Neurology, vol. 77, no. 17, pp. 1611–1618, 2011. View at Publisher · View at Google Scholar
  23. L. Steinman, “Assessment of animal models for MS and demyelinating disease in the design of rational therapy,” Neuron, vol. 24, no. 3, pp. 511–514, 1999. View at Google Scholar · View at Scopus
  24. T. Olsson, “Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis,” Neurology, vol. 45, no. 6, supplement 6, pp. S11–15, 1995. View at Google Scholar · View at Scopus
  25. H. McDevitt, “Specific antigen vaccination to treat autoimmune disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, supplement 2, pp. 14627–14630, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. H. L. Weiner, A. Friedman, A. Miller et al., “Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens,” Annual Review of Immunology, vol. 12, pp. 809–837, 1994. View at Google Scholar · View at Scopus
  27. D. J. Cua, D. R. Hinton, and S. A. Stohlman, “Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice: Th2-mediated suppression of autoimmune disease,” Journal of Immunology, vol. 155, no. 8, pp. 4052–4059, 1995. View at Google Scholar · View at Scopus
  28. G. X. Zhang, H. Xu, M. Kishi, D. Calida, and A. Rostami, “The role of IL-12 in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 168, no. 5, pp. 2501–2507, 2002. View at Google Scholar · View at Scopus
  29. G. X. Zhang, S. Yu, Y. Li, E. S. Ventura, B. Gran, and A. Rostami, “A paradoxical role of APCs in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 161, no. 1-2, pp. 101–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Smolders, J. Damoiseaux, P. Menheere, and R. Hupperts, “Vitamin D as an immune modulator in multiple sclerosis, a review,” Journal of Neuroimmunology, vol. 194, no. 1-2, pp. 7–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Smolders, J. Damoiseaux, P. Menheere, and R. Hupperts, “Vitamin D as an immune modulator in multiple sclerosis, a review,” Journal of Neuroimmunology, vol. 194, pp. 401–428, 86. View at Publisher · View at Google Scholar · View at Scopus
  32. A. J. Solomon and R. H. Whitham, “Multiple sclerosis and vitamin D: a review and recommendations,” Current Neurology and Neuroscience Reports, vol. 10, no. 5, pp. 389–396, 2010. View at Publisher · View at Google Scholar · View at Scopus